Clinical trials: Escherichia Coli Infections
Human Papillomavirus Infection
A Phase I Trial Evaluate the Safety and Tolerability Profile of HPV Vaccine
This study is to evaluate the safety and tolerability profile of Recombinant Nonavalent (Types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia Coli) in healthy women ages 18-45
- Trial name
- NCT05680454
- Testing
- Recombinant Nonavalent (Types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia Coli), Recombinant nonavalent Human Papillomavirus (Types 6,11,16,18,31,33,45,52,58) Vaccine
- Where
- China
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Beijing Health Guard Biotechnology, Inc
Drug Resistance, Microbial
Quinolone Resistance Profiles and Mechanisms of Staphylococcus Aureus and Escherichia Coli From Humans, Chicken and Catfish Farms in Indonesia
The goal of this observational study is to reveal quinolone resistance profiles and mechanisms in S. aureus and E. coli in the human, animal and aquaculture sector in Blitar, Indonesia.
- Trial name
- QUINDO (NCT05652556)
- Volunteers
- 480 people, healthy volunteers welcome
- Sponsor
- Erasmus Medical Center
Enterotoxigenic Escherichia Coli Infection, Diarrhea
Study Confirming A Human Challenge Model and Investigating The Safety Of VLA1701
This is a single-center, double-blind, placebo-controlled, Phase II vaccination and challenge study designed to confirm a human challenge model with E. coli strain LSN03-016011/A.
- Trial name
- NCT03576183
- Testing
- VLA1701, Challenge Strain
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Valneva Austria GmbH
Hemolytic-uremic Syndrome, Escherichia Coli Infections
Outbreak of Hemolytic Uremic Syndrome Linked to Escherichia Coli of Serotype O104:H4
The Hemolytic Uremic Syndrome (HUS) in its typical form occurs after a food born infection with a shiga-toxin secreting bacteria, usually Escherichia coli of the O157H7 serotype.
- Trial name
- SHU O104 CUB (NCT01406288)
- Testing
- HUS standard coverage care (including in ICU)
- Where
- France
- Volunteers
- 9 people
- Sponsor
- University Hospital, Bordeaux
Healty Volunteers, Preventable Disease, Vaccine
A Phase 2 Bridging Study to Assess the New Formulation of ETVAX
This is a phase 2,prospective double-blind, randomized, parallel-group study with the aim to demonstrate non-inferiority, in terms of immunogenicity, between the wet formulation and a newly developed partially dried formulation…
- Trial name
- NCT05178134
- Testing
- Etvax
- Where
- Sweden
- Volunteers
- 280 people, healthy volunteers welcome
- Sponsor
- Scandinavian Biopharma AB
Infection Due to ESBL Escherichia Coli
Fosfomycin Versus Meropenem or Ceftriaxone in Bacteriemic Infections Caused by Multidrug Resistance in E.Coli
Enterobacterieaceae (and specially Escherichia coli) showing resistance due to multidrug-resistant Escherichia coli, plasmid mediated AmpC or quinolone resistance caused by chromosomal mechanisms have spread worldwide during the…
- Trial name
- FOREST (NCT02142751)
- Testing
- Fosfomycin sodium intravenous, Meropenem intravenous, Ceftriaxone intravenous
- Where
- 22 sites in Spain
- Volunteers
- 161 people
- Sponsor
- Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Cervical Cancer, Condylomata Acuminata
An Immuno-bridging Study of a Nonavalent HPV Vaccine (E.Coli) in Healthy Population Aged 9-17 vs Aged 18-26 Years Old
This is a open label clinical trial to evaluate the safety and immunogenicity of a Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58)Vaccine(E.Coli) manufactured by Xiamen Innovax Biotech CO., Ltd., in…
- Trial name
- NCT05056402
- Testing
- 3 doses of the Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58 )Vaccine(E.Coli), 2 doses of theRecombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58 )Vaccine(E.Coli)
- Where
- China
- Volunteers
- 1,382 people, healthy volunteers welcome
- Sponsor
- Xiamen University
Diarrhea Infectious
Study in Healthy Adults Challenged With Enterotoxigenic E. Coli, of the Safety, Tolerability and Anti-Diarrheal Activity of VENBETA6890, an Orally Administered, Human Monoclonal IgA
This is a phase 1, randomized, placebo-controlled, blinded study in up to 36 healthy adults, aged 18-45 years, challenged with Enterotoxigenic Escherichia coli, evaluating the safety, tolerability and anti-diarrheal activity of…
- Trial name
- MBL-ETEC-21-01 (NCT06896136)
- Testing
- VENBETA6890
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Mark Klempner
Carriage of ESBL-positive Escherichia Coli, Carriage of ESBL-positive Klebsiella Pneumoniae
Extended Tricyle Project Indonesia for Extended-spectrum Beta-lactamase Positive Klebsiella Pneumoniae and Escherichia Coli
In 2019, Indonesia's first WHO Tricycle Project revealed alarming rates of extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli across various sectors. The study found ESBL-producing E.
- Trial name
- E-Trike (NCT07106944)
- Testing
- Community pregnant women: rectal and throat swab
- Volunteers
- 100 people
- Sponsor
- Erasmus Medical Center
Escherichia Coli Bloodstream Infection
Prognostic Factors of Escherichia Coli Bloodstream Infections: Severity Score and Therapeutic Implications
The determinants associated with severe outcome and death from Escherichia coli bloodstream infections (BSI) remain poorly understood. The epidemiology of E.
- Trial name
- SEPTICOLI (NCT02890901)
- Where
- France
- Volunteers
- 553 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Urinary Tract Infections
Urinary Tract Infection in Pregnancy
to describe the profile of uropathogenic E coli from Egyptian pregnant women with UTIs and a symptomatic bacteriuria. to determine the susceptibility pattern of our local isolated UPEC strains which is essential for optimal…
- Trial name
- NCT04244526
- Testing
- Talking a urine sample
- Volunteers
- 155 people
- Sponsor
- Assiut University
Diarrhea
Dose Escalating Study of a Prototype CS6 Subunit Vaccine With a Modified Heat-labile Enterotoxin From Enterotoxigenic Escherichia Coli (ETEC)
This study will evaluate the safety of a prototype Coli surface antigen 6 (CS6) subunit vaccine (CssBA) alone or in combination with Escherichia coli double mutant heat labile toxin (dmLT) given by intramuscular (IM) injection.
- Trial name
- NCT03404674
- Testing
- CssBA, dmLT
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- PATH
Cervical Intraepithelial Neoplasia, Cervical Cancer
Lot Consistency Clinical Trial of of Recombinant HPV Bivalent Vaccine in 9 to14 Years Old Healthy Female
This study is to evaluate lot-lot consistency of Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Escherichia coli) .
- Conditions
- Cervical Intraepithelial Neoplasia, Cervical Cancer, Vaginal Intraepithelial Neoplasia, Vulvar Intraepithelial Neoplasia
- Trial name
- NCT05426148
- Testing
- Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Escherichia coli) / Cecolin®
- Where
- China
- Volunteers
- 540 people, healthy volunteers welcome
- Sponsor
- Xiamen Innovax Biotech Co., Ltd
Urinary Tract Infection(UTI)
E. Coli for Prevention of Catheter UTI in SCI Patients
The overall goal of this project is to develop a new approach for the prevention of urinary tract infection (UTI) in persons who rely on indwelling catheters for bladder drainage.
- Trial name
- NCT00458471
- Testing
- Insertion of a urinary catheter coated with benign E. coli
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Cervical Intraepithelial Neoplasia, Cervical Cancer
Immuno-persistence Study of a Recombinant Human Papillomavirus 16/18 Bivalent Vaccine in Preadolescent Girls (54m)
The primary objective of this study is to evaluate the immuno-persistence (type specific IgG antibody) of the tested vaccine administered in girls aged 9-17 years,comparing to young healthy adults of 18-26 years who received the…
- Conditions
- Cervical Intraepithelial Neoplasia, Cervical Cancer, Vaginal Intraepithelial Neoplasia, Vulvar Intraepithelial Neoplasia
- Trial name
- NCT04704908
- Testing
- Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Escherichia coli)
- Where
- China
- Volunteers
- 979 people
- Sponsor
- Jun Zhang
Antibiotic Sensitivity Testing and Genotypic Caharacterization of Ecoli
Phenotypic and Genotypic Characterization of Escherichia Coli
Collection of urine samples Cultivation Antibiotic sensitivity test PCR
- Trial name
- NCT06462261
- Volunteers
- 100 people
- Sponsor
- Sohag University
Hepatitis E
Phase Ⅳ Clinical Trial of Recombinant Hepatitis E Vaccine（Hecolin®）
The purpose of this study is to determine the safety and immunogenicity of the recombinant hepatitis E vaccine in people older than 65 years, and evaluate the efficacy of hepatitis E vaccine in this population.
- Trial name
- NCT02189603
- Testing
- Recombinant (E. Coli) Hepatitis E Vaccine
- Where
- China
- Volunteers
- 601 people, healthy volunteers welcome
- Sponsor
- Jun Zhang
Enteritis; Escherichia Coli, Enterotoxigenic
Challenge Study of an ETEC Vaccine
The purpose of the study is to determine the efficacy of a vaccine against enterotoxigenic E. coli (ETEC)-caused diarrhea.
- Trial name
- NCT01922856
- Testing
- LTR192G with dscCfaE, No Intervention
- Where
- 2 sites in United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
Gastroenteritis, Bacterial Infection
The Effect of Probiotics on E. Coli Gastroenteritis
Background: The incidence of gastrointestinal infections is very high. In European countries 10-25% of the population suffers from at least one foodborne infection per year.
- Conditions
- Gastroenteritis, Bacterial Infection, Diarrhea
- Trial name
- PRETEC (NCT01225042)
- Testing
- probiotics
- Where
- Netherlands
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- NIZO Food Research
Human Papilloma Virus Infection Type 16, Human Papilloma Virus Infection Type 18
The Immunogenicity and Safety of the Vaccination of Human Papillomavirus Vaccine and Measles-Mumps-Rubella Vaccine
The purpose of this study is to evaluate the immunogenicity and safety of Recombinant Human Papillomavirus Bivalent (Types 16,18) Vaccine (Escherichia coli) （HPV）and Measles Mumps and Rubella Combined Vaccine, Live（MMR）
- Conditions
- Human Papilloma Virus Infection Type 16, Human Papilloma Virus Infection Type 18, Measles, Rubella
- Trial name
- NCT05279248
- Testing
- HPV+MMR（0d），HPV（6m）, HPV（0d），HPV（6m），MMR（7m）, MMR（0d），HPV（1m），HPV（7m）
- Where
- 2 sites in China
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Zhejiang Provincial Center for Disease Control and Prevention